Why is ERIS Lifescience falling/rising?

As of 17-Sep, ERIS Lifesciences Ltd is experiencing a decline in its stock price, currently at 1,645.25, reflecting a decrease of 15.75 points or 0.95%. The stock has underperformed its sector today by 0.99%, and its delivery volume has fallen by 17.06% compared to the 5-day average, indicating reduced investor participation. Despite this, the company has demonstrated strong financial metrics, including a high return on capital employed (ROCE) of 17.80% and a low debt to EBITDA ratio of 1.15 times, which suggests a solid ability to manage debt. Over the past year, the stock has outperformed the broader market, generating an 18.70% return while the market has seen a decline of 0.46%.
In the broader market context, the stock's recent performance contrasts with the benchmark, as it has declined by 4.28% over the past week while the Sensex has increased by 1.56%. This underperformance in the short term may be contributing to the stock's current price drop, despite its strong year-to-date performance of 20.19%. The market's overall positive trend may not be benefiting ERIS Lifesciences as much as other stocks, which could be influencing investor sentiment and leading to the current decline in price.